Publications
groupedSurv: Efficient Estimation of Grouped Survival Models Using the Exact Likelihood Function (R). 1.0.0 ed., 2018.
Greedy outcome weighted tree learning of optimal personalized treatment rules." Biometrics 73, no. 2 (2017): 391-400.
" Goodness-Of-Fit Test for Nonparametric Regression Models: Smoothing Spline ANOVA Models as Example." Comput Stat Data Anal 122 (2018): 135-155.
"A global sensitivity test for evaluating statistical hypotheses with nonidentifiable models." Biometrics 66, no. 2 (2010): 558-66.
"A global logrank test for adaptive treatment strategies based on observational studies." Stat Med 33, no. 5 (2014): 760-71.
"Global copy number profiling of cancer genomes." Bioinformatics 32, no. 6 (2016): 926-8.
" GGMridge: Gaussian graphical models using ridge penalty followed by thresholding and reestimation (R).. 1.0 ed., 2016.
Genomewide Meta-Analysis Validates a Role for S1PR1 in Microtubule Targeting Agent-Induced Sensory Peripheral Neuropathy." Clin Pharmacol Ther 108, no. 3 (2020): 625-634.
"A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101." Clin Cancer Res 18, no. 18 (2012): 5099-109.
""Genome-wide association study identifies five new schizophrenia loci." Nat Genet 43, no. 10 (2011): 969-76.
Genome analysis and pleiotropy assessment using causal networks with loss of function mutation and metabolomics." BMC Genomics 20, no. 1 (2019): 395.
" Genetic variation determines VEGF-A plasma levels in cancer patients." Sci Rep 8, no. 1 (2018): 16332.
"Genetic association analysis under complex survey sampling: the Hispanic Community Health Study/Study of Latinos." Am J Hum Genet 95, no. 6 (2014): 675-88.
"Genetic analyses of diverse populations improves discovery for complex traits." Nature 570, no. 7762 (2019): 514-518.
" Generation of a Transcriptional Radiation Exposure Signature in Human Blood Using Long-Read Nanopore Sequencing." Radiat Res 193, no. 2 (2020): 143-154.
"A general framework for studying genetic effects and gene-environment interactions with missing data." Biostatistics 11, no. 4 (2010): 583-98.
"A general framework for integrative analysis of incomplete multiomics data." Genet Epidemiol 44, no. 7 (2020): 646-664.
"A general framework for detecting disease associations with rare variants in sequencing studies." Am J Hum Genet 89, no. 3 (2011): 354-67.
"A general framework for association tests with multivariate traits in large-scale genomics studies." Genet Epidemiol 37, no. 8 (2013): 759-67.
"GENE-LEVEL PHARMACOGENETIC ANALYSIS ON SURVIVAL OUTCOMES USING GENE-TRAIT SIMILARITY REGRESSION." Ann Appl Stat 8, no. 2 (2014): 1232-1255.
"Gene set analysis methods: a systematic comparison." BioData Min 11 (2018): 8.
"Gene selection using iterative feature elimination random forests for survival outcomes." IEEE/ACM Trans Comput Biol Bioinform 9, no. 5 (2012): 1422-31.
"Galax (C++)., 2016.
Functional-mixed effects models for candidate genetic mapping in imaging genetic studies." Genet Epidemiol 38, no. 8 (2014): 680-91.
"Functional Linear Regression Models for Nonignorable Missing Scalar Responses." Stat Sin 28, no. 4 (2018): 1867-1886.
"Functional feature construction for individualized treatment regimes." J Am Stat Assoc 113, no. 523 (2017): 1219-1227.
"FSR Methods for Second-Order Regression Models." Comput Stat Data Anal 55, no. 6 (2011): 2026-2037.
"FSEM: Functional Structural Equation Models for Twin Functional Data." J Am Stat Assoc 114, no. 525 (2019): 344-357.
"A framework for understanding cancer comparative effectiveness research data needs." J Clin Epidemiol 65, no. 11 (2012): 1150-8.
"A framework for transcriptome-wide association studies in breast cancer in diverse study populations." Genome Biol 21, no. 1 (2020): 42.
"FMEM: functional mixed effects modeling for the analysis of longitudinal white matter Tract data." Neuroimage 84 (2014): 753-64.
"Flexible stopping boundaries when changing primary endpoints after unblinded interim analyses." J Biopharm Stat 24, no. 4 (2014): 817-33.
"Flexible longitudinal linear mixed models for multiple censored responses data." Stat Med 38, no. 6 (2019): 1074-1102.
"FLCRM: Functional linear cox regression model." Biometrics 74, no. 1 (2018): 109-117.
" Fixed and random effects selection in mixed effects models." Biometrics 67, no. 2 (2011): 495-503.
"Fitting Nonlinear Ordinary Differential Equation Models with Random Effects and Unknown Initial Conditions Using the Stochastic Approximation Expectation-Maximization (SAEM) Algorithm." Psychometrika 81, no. 1 (2016): 102-34.
"Fitting Cox Models with Doubly Censored Data Using Spline-Based Sieve Marginal Likelihood." Scand Stat Theory Appl 43, no. 2 (2016): 476-486.
" FEATURE ELIMINATION IN KERNEL MACHINES IN MODERATELY HIGH DIMENSIONS." Ann Stat 47, no. 1 (2019): 497-526.
" fastJT: Efficient Jonckheere-Terpstra Test Statistics for Robust Machine Learning and Genome-Wide Association Studies (R). 1.0.4 ed., 2017.
fastJT: An R package for robust and efficient feature selection for machine learning and genome-wide association studies." BMC Bioinformatics 20, no. 1 (2019): 333.
" A Fast Multiple-Kernel Method With Applications to Detect Gene-Environment Interaction." Genet Epidemiol 39, no. 6 (2015): 456-68.
"Fast Bayesian Variable Screenings for Binary Response Regressions with Small Sample Size." J Stat Comput Simul 87, no. 14 (2017): 2708-2723.
"False discovery rate control for high dimensional networks of quantile associations conditioning on covariates." J R Stat Soc Series B Stat Methodol 80, no. 5 (2018): 1015-1034.
"Failure time regression with continuous informative auxiliary covariates." J Stat Distrib Appl 2 (2015): 2.
"FADTTS: functional analysis of diffusion tensor tract statistics." Neuroimage 56, no. 3 (2011): 1412-25.
"Factor selection and structural identification in the interaction ANOVA model." Biometrics 69, no. 1 (2013): 70-9.
"Facilitating the Calculation of the Efficient Score Using Symbolic Computing." Am Stat 72, no. 2 (2018): 199-205.
"An Exponential Bound for Cox Regression." Stat Probab Lett 82, no. 7 (2012): 1267-1272.
"Exploiting expression patterns across multiple tissues to map expression quantitative trait loci." BMC Bioinformatics 17 (2016): 257.
"An Expectation Maximization algorithm for fitting the generalized odds-rate model to interval censored data." Stat Med 36, no. 7 (2017): 1157-1171.
" Evaluating Statistical Hypotheses Using Weakly-Identifiable Estimating Functions." Scand Stat Theory Appl 40, no. 2 (2013): 256-273.
"Evaluating personalized treatment regimes." In Methods in Comparative Effectiveness Research. New York: Chapman and Hall/CRC, 2017.
"Evaluating haplotype effects in case-control studies via penalized-likelihood approaches: prospective or retrospective analysis?" Genet Epidemiol 34, no. 8 (2010): 892-911.
"Estimation of treatment effects and model diagnostics with two-way time-varying treatment switching: an application to a head and neck study." Lifetime Data Anal 26, no. 4 (2020): 685-707.
"Estimation of treatment effect for the sequential parallel design." Stat Med 30, no. 30 (2011): 3496-506.
"ON ESTIMATION OF THE OPTIMAL TREATMENT REGIME WITH THE ADDITIVE HAZARDS MODEL." Stat Sin 28, no. 3 (2018): 1539-1560.
"On Estimation of Optimal Treatment Regimes For Maximizing -Year Survival Probability." J R Stat Soc Series B Stat Methodol 79, no. 4 (2017): 1165-1185.
" Estimation of optimal dynamic treatment regimes." Clin Trials 11, no. 4 (2014): 400-407.
"Estimation of dynamic treatment regimes for complex outcomes: Balancing benefits and risks." In Adaptive Treatment Strategies in Practice: Planning Trials and Analyzing Data for Personalized Medicine, 249-262. Philadelphia: ASA-SIAM, 2016.
"Estimation of AUC or Partial AUC under Test-Result-Dependent Sampling." Stat Biopharm Res 4, no. 4 (2012): 313-323.
"Estimation of a partially linear additive model for data from an outcome-dependent sampling design with a continuous outcome." Biostatistics 17, no. 4 (2016): 663-76.
"Estimation After a Group Sequential Trial." Stat Biosci 7, no. 2 (2015): 187-205.
"Estimating treatment effects with treatment switching via semicompeting risks models: an application to a colorectal cancer study." Biometrika 99, no. 1 (2012): 167-184.
" Estimating Treatment Effects for Recurrent Events in the Presence of Rescue Medications: An Application to the Immune Thrombocytopenia Study." Stat Biosci 10, no. 2 (2018): 473-489.
"Estimating time-varying effects for overdispersed recurrent events data with treatment switching." Biometrika 100, no. 2 (2013): 339-354.
"Estimating the subgroup and testing for treatment effect in a post-hoc analysis of a clinical trial with a biomarker." J Biopharm Stat 29, no. 4 (2019): 685-695.
"Estimating personalized diagnostic rules depending on individualized characteristics." Stat Med 36, no. 7 (2017): 1099-1117.
"Estimating Optimal Treatment Regimes from a Classification Perspective." Stat 1, no. 1 (2012): 103-114.
" Estimating Individualized Treatment Rules Using Outcome Weighted Learning." J Am Stat Assoc 107, no. 449 (2012): 1106-1118.
"Estimating individualized treatment rules for ordinal treatments." Biometrics 74, no. 3 (2018): 924-933.
"Estimating individualized treatment regimes from crossover designs." Biometrics 76, no. 3 (2020): 778-788.
"Estimating effect of environmental contaminants on women's subfecundity for the MoBa study data with an outcome-dependent sampling scheme." Biostatistics 15, no. 4 (2014): 636-50.
"Estimating Dynamic Treatment Regimes in Mobile Health Using V-learning." J Am Stat Assoc 115, no. 530 (2020): 692-706.
"Estimating Bayesian Phylogenetic Information Content." Syst Biol 65, no. 6 (2016): 1009-1023.
"Establishment of reference standards in biosimilar studies." GaBI J 2, no. 4 (2013): 173-177.
"Environmental and genetic contributors to salivary testosterone levels in infants." Front Endocrinol (Lausanne) 5 (2014): 187.
"Entropy Learning for Dynamic Treatment Regimes." Stat Sin 29, no. 4 (2019): 1633-1655.
"Enrollment Trends and Disparity Among Patients With Lung Cancer in National Clinical Trials, 1990 to 2012." J Clin Oncol 34, no. 33 (2016): 3992-3999.
"Enrollment and Stopping Rules for Managing Toxicity Requiring Long Follow-Up in Phase II Oncology Trials." J Biopharm Stat 25, no. 6 (2015): 1206-14.
"On Enrichment Strategies for Biomarker Stratified Clinical Trials." J Biopharm Stat 28, no. 2 (2018): 292-308.
"Enriched biomarker-driven clinical trials. In Wiley StatsRef: Statistics Reference Online. Wiley, 2019.
Endpoints for cancer clinical trials." In Cancer Clinical Trials: Current and Controversial Issues in Design and Analysis. Boca Raton: Chapman & Hall / CRC Press, 2016.
"